Studies in kidney have shown that miR-93* also targets vascular epithelial growth factor-A (VEGF) (63), a cytokine associated with hematopoietic cancer outcome, immune modulation, and tissue repair (64, 65). The gene discussed is VEGFA; the disease is hematopoietic and lymphoid cell neoplasm.